Site Editor
Leo I. Gordon, MD, FACP
Leo I. Gordon, MD, FACP
Posted: Thursday, February 23, 2023
According to research presented in Oncotarget, mutation analysis performed on biopsied B-cell tumors may help predict which molecular subtypes are likely to be associated with inferior survival outcomes. Patients with newly diagnosed germinal center B-cell diffuse large B-cell or high-grade B-cell lymphoma may benefit from undergoing comprehensive genomic analysis of tumor biopsies via clinical laboratory mutation analysis to determine whether they belong to a poor-risk molecular subgroup, such as those harboring a CREBBP mutation.
“Furthermore, clinical laboratory mutation analysis may be practically applied to translate experimental findings into those with more direct application to risk stratification and clinical trial design in subsets of patients with [diffuse large B-cell lymphoma/high grade B-cell lymphoma],” concluded Daniel J. Landsburg, MD, of the University of Pennsylvania, Philadelphia, and colleagues.
The study included 59 tumor biopsies gathered between 2015 and 2021, 58 of which underwent successful assays. Overall, 51 biopsies from 51 patients were eligible for analysis. The median result turnaround time was 16 days. Analyses were performed using the lymphoma sequencing panel (n = 32) or the PennSeq lymphoma panel (n = 19).
Overall, 21 CREBBP, 18 TP53, 12 EZH2, and 11 TNFRSF14 mutations, among 24 assorted others, were identified. The presence of CREBBP mutations was associated with poorer rates of disease-free survival. At a median follow-up of 25.2 months, the estimated rate of 2-year disease-free survival was 45% for patients with CREBBP mutations versus 67% for patients without such mutations. The estimated 2-year overall survival was comparable between the two groups. Of note, all patients harboring a CREBBP mutation who experienced relapse did so within 12 months of diagnosis.
Disclosure: For full disclosures of the study authors, visit oncotarget.com.
